Abstract Invasive fusariosis (IF) is a rare but aggressive infection seen in immunocompromised patients that often exhibits elevated minimum inhibitory concentrations (MICs) to antifungal drugs, making the optimal therapeutic remains unknown. We identified all cases of IF between January 2015 and April 2024 and collected patient characteristics, including clinical presentation, therapy, and 12-week outcomes, as well as organism species identification and susceptibility testing. Twenty-one patients were diagnosed with either proven (n = 14) or probable (n = 7) IF. The mean age was 60 years and 71% were male. Hosts had hematologic disorders in 71% of which 80% had acute leukemia. Seventy-three percent were neutropenic at the time of IF diagnosis and 40% had received allogeneic stem cell transplantation. Infections were localized in 57% and disseminated in 43%. Skin was the most common site of involvement (67%), followed by pulmonary (42%) and sinus (21%). The most common species was Fusarium solani complex (38%). Susceptibility testing was performed on 81% of isolates. MICs were ≥4 µg/mL for mold-active triazoles in 94% and ≥1 µg/mL for terbinafine in 65%. The most common definitive regimens were a triazole plus terbinafine (62%) and triazole monotherapy (19%). Surgical debridement was performed in 52%. Seventy-six percent of patients survived to 12 weeks. Fifty-seven percent achieved complete responses, 29% partial responses, and 14% failed to respond to therapy at 12 weeks. Mortality in patients with IF is high. Despite elevated MICs, clinical responses to triazole antifungals with or without the addition of terbinafine are observed.
Kovac et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: